SCHEMBL3933903

SCHEMBL3933903

CN(C)Cc1ccc(N/C(=C2\C(=O)Nc3ccccc32)c2ccc3c(c2)nnn3C)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 6/20 0.45
ALDH1A1 P00352 4/20 0.45
MAPK1 P28482 1/20 0.45
KDM4E B2RXH2 5/20 0.43
HSD17B10 Q99714 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
NPC1 O15118 4/20 0.42
HPGD P15428 4/20 0.39
AHR P35869 1/20 0.38
HCAR3 P49019 1/20 0.38
SLC2A1 P11166 1/20 0.37
POLB P06746 2/20 0.37
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933909 1.00 RAB9A (0.46) RAB9AMEN1KMT2AMAPTALDH1A1
SCHEMBL3943293 0.86 SLC2A1 (0.42) RAB9AKMT2AMAPTALDH1A1KDM4E
SCHEMBL3943289 0.86 SLC2A1 (0.42) RAB9AKMT2AMAPTALDH1A1KDM4E
SCHEMBL3933896 0.84 RAB9A (0.46) RAB9AMEN1KMT2AMAPTALDH1A1
SCHEMBL3933394 0.81 SLC2A1 (0.40) RAB9AMEN1KMT2AMAPTMAPK1
SCHEMBL30979384 0.81 IDO1 (0.40) MAPTALDH1A1SMN1; SMN2
SCHEMBL6323531 0.81 IDO1 (0.40) MAPTALDH1A1SMN1; SMN2
SCHEMBL6323528 0.81 IDO1 (0.40) MAPTALDH1A1SMN1; SMN2
SCHEMBL6326859 0.80 MAPT (0.41) RAB9AMEN1KMT2AMAPTALDH1A1
SCHEMBL6326854 0.80 MAPT (0.41) RAB9AMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 RAB9A 3709/4885MEN1 1664/4885KMT2A 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.